Outcomes after VEN-based regimens for patients with cBTKi-exposed CLL. (A) PFS and OS for patients who received VEN-R; (B) PFS and OS for patients who received VEN monotherapy; and (C) PFS, stratified by TP53 status for patients receiving VEN-based therapy.